RESUMO
Humans are experiencing serious health issues like myocardial infarction and diabetes. Thrombosis is the reason of myocardial infarction that may cause death. Bioactive compounds or enzymes can be used to dissolve the clot. Whereas diabetes is a disorder of metabolism in which the level of glucose in blood becomes high. It can be controlled by inhibiting α-amylase enzyme. The current project was, therefore planned to investigate the thrombolytic, α-amylase inhibitory and cytotoxic (to access drug safety) potentials of the organic and aqueous bioactive fractions of Bacillus clausii KP10. The cytotoxicity was assessed with hemolytic assay, α-amylase inhibition assay was done by using DNS and in-vitro thrombolytic effect was checked with human blood. In our experiments, the maximum hemolytic activity was shown by ethyl acetate fraction (12.64%). Results were compared with standard Triton X-100 which showed 91.61% hemolytic activity whereas all other fractions showed least cytotoxic activity. The extracts were also evaluated as thrombolytic agents as correlated to streptokinase (73.83%). All the extracts showed clot lysis activity, among which water soluble fraction exhibited maximum (35.16%) clot lysis activity. In our experiment methanol soluble fraction of B. clausii KP10 showed maximum 26.49% α-amylase inhibitory activity. Results were analyzed statistically through analysis of variance (ANOVA).